Bone's hard nature and low porosity makes it difficult to deliver adequate quantities of drugs. Our unique bone targeting drug delivery technology can revolutionise the way in which clinical conditions of bone are treated. We are developing products to treat conditions such as osteoporosis, myelofibrosis, cancer metastases and infection. Strategy is to obtain early clinical data in dental bone regeneration and an orphan indication.